首页> 外文OA文献 >163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)

【2h】

163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)

机译：163P人口调整的太阳能-1和Bolero-2的比较：PFS与二线alpelisib +富勒斯特语+ Everolimus + Extemestane在绝经后PTS，PIK3CA-MUT激素受体阳性（HR +）人体表皮生长因子受体-2阴性（HER2 - ）晚期乳腺癌（ABC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
E.M. Ciruelos; T. Delea; A. Moynahan; I. Mayer; J. Park; D. Chandiwana; A. Ridolfi; I. Lorenzo; H.S. Rugo;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial [J] . Prat A., Brase J. C., Cheng Y., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：PAM50在激素受体阳性（HR Plus）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）中的蛋白质亚型（EXE）与Everolimus（EVE）或安慰剂（PBO）组合处理： III阶段Bolero-2试验的相关分析
2. Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 [J] . Nadia Harbeck, Marco Colleoni, Angela Demichele, The Breast : . 2017,第期

机译：Palbociclib（PAL）Pus Fulvestrant（F）对患有内分泌激素受体阳性（HR +）的地理区域，人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）的疗效和来自帕拉马的患者 - 3.
3. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 [J] . Piccart M., Hortobagyi G. N., Campone M., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第12期

机译：依维莫司加依西美坦治疗激素受体阳性，人表皮生长因子受体-2-阴性的晚期乳腺癌：BOLERO-2的总体生存率
4. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
5. Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive human epidermal growth factor receptor-2–negative advanced breast cancer in Europe [O] . Guy Jerusalem, Patrick Neven, Nina Marinsek, 2015

机译：欧洲绝经后激素受体阳性人表皮生长因子受体-2阴性的晚期乳腺癌妇女的资源利用和成本模式
6. PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE [O] . A. Buehler, H.S.J. Kim, L. Fahham, 2019

机译：PCN160 Ribociclib的成本效果加上Letrozole与Palbociclib加仑唑唑加上患有激素受体阳性/人表皮生长因子受体2阴性（HR + / HER2-）先进或转移性乳腺癌（ABC）的前代妇女：巴西私人付款人的角度

163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)

著录项

引文网络

相似文献

相关主题

期刊订阅